2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, CHIP, Genomics, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, T Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

792 ST-001 nanoFenretinideTM demonstrates clinical activity with a differentiated safety profile in heavily pretreated relapsed/refractory cutaneous T-cell lymphoma: Preliminary results from a first-in-human Phase 1a study

Larisa J. Geskin, MD, Oleg Akilov, MD2, Christiane Simone Querfeld, MD, PhD3, Auris O. Huen, MD, PharmD4, Barbara Pro, MD5, Dipenkumar Modi, MD6, Ann Mohrbacher, MD7, Bradley Haverkos, MD8, Aaron Mangold, MD9, Lou Scarmoutzos, PhD10, Michael Burns, PhD11, Earle Holsapple12, Kenneth Massey, PhD13, Yamini Donekal, MBBS, MS14, Ralph Parchment, PhD15, Ali Moiin, MD16
1 Columbia University, New York, United States
2 University of Pittsburgh Medical Center, Pittsburg, United States
3 City of Hope National Medical Center, Duarte, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 Columbia University, New York, United States
6 Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, United States
7 University of Southern California, Los Angeles, United States
8 University of Colorado, Aurora, United States
9 Mayo Clinic, Scottsdale, United States
10 SciTech Development Inc, Grosse Pointe Farms, United States
11 SciTech Development Inc, Grosse Pointe Farms, United States
12 SciTech Development Inc, Grosse Pointe Farms, United States
13 SciTech Development Inc, Grosse Pointe Farms, United States
14 SciTech Development Inc, Grosse Pointe Farms, United States
15 SciTech Development Inc, Grosse Pointe Farms, United States
16 SciTech Development Inc, Grosse Pointe Farms, United States

Introduction

Patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), have limited options after failure of approved systemic therapies. Intravenous (IV) fenretinide (4-HPR) has demonstrated antitumor activity in CTCL, including after bexarotene therapy, but development of an earlier IV formulation was limited by excipient-related dose-limiting toxicity. ST-001 nanoFenretinide (ST-001) is a patented phospholipid nanoparticle formulation designed to optimize delivery and tolerability of IV fenretinide. We report preliminary safety, pharmacokinetics (PK), antitumor activity, and recommended treatment dose of ST-001 in CTCL from the first-in-human phase 1a trial (NCT04234048).

Methods

This multicenter, accelerated dose-escalation phase 1a study enrolled patients with R/R T-cell non-Hodgkin lymphoma, including CTCL (MF and SS). Escalating dose levels of ST-001 from 1.25 to 1,756 mg/m²/day were administered IV via 4-hour infusion, daily for five consecutive days, every 21-day cycle for up to eight cycles. Primary objectives were safety, tolerability, and the maximum tolerated dose. Secondary objectives included preliminary antitumor activity, the recommended treatment dose, PK of fenretinide and its metabolites, and exploratory pharmacodynamic (Pd) biomarkers in skin biopsies.

Results

Twenty-nine participants with CTCL received ST-001 [median age, 59 years (range, 28–86)]; 24 had MF and 5 had SS. Patients were heavily pretreated: 24 (83%) had received ≥3 prior systemic therapies, most commonly bexarotene, methotrexate, brentuximab vedotin, and HDAC inhibitors; some had received interferon, mogamulizumab, and photopheresis.

Across all doses, the objective response rate was 34% (10 of 29), including one complete response (CR), eight confirmed partial responses (cPR), and one unconfirmed partial response (uPR). Among patients treated at the three highest dose levels (DL 11-13), the objective response rate increased to 47% (8 of 17; 1 CR, 6 cPR, 1 uPR). Five of the ten responses were maintained through eight treatment cycles (maximum length of therapy), demonstrating sustained clinical activity in this heavily pretreated population.

ST-001 was well tolerated across all dose levels. No treatment-related deaths occurred, and no clinically significant hematologic toxicity/cytopenias/sepsis, or cardiac, neurologic, or pulmonary toxicity occurred. Treatment-related hypertriglyceridemia was grade ≤1, and ocular toxicity was grade ≤2. At dose levels up to 640 mg/m²/day, the only grade 3 treatment-related adverse event was ulceration over CTCL lesions in one patient. At 896 mg/m²/day, grade 3 events of bone pain, back pain, hypercholesterolemia, and acute kidney injury occurred (n=1 each). At 1,254 mg/m²/day, hypercholesterolemia occurred in 4 patients (grade 4, n=3; grade 3, n=1), with single grade 3 events of nausea, vomiting, hepatobiliary disorder, and AST/ALT increase; hypercholesterolemia was reversible within the 21-day cycle and manageable with concomitant medications, and grade 2 ocular TRAEs (nyctalopia) occurred in 4 patients. At the highest planned dose level (1,756 mg/m²/day), 3 of 4 patients required dose reduction for grade 2 nausea or dizziness. The only AE-related discontinuation was a withdrawal for grade 2 nyctalopia that resolved after treatment discontinuation.

Pd biomarker analysis is pending. Tissue delivery of fenretinide was rapid, as evidenced by the appearance of a major fenretinide metabolite by the end of infusion. PK analyses demonstrated dose-dependent systemic exposure; higher dose levels achieved plasma fenretinide concentrations approaching 200 μM.

Conclusions

ST-001 demonstrated single-agent activity in heavily pretreated patients with R/R CTCL, producing sustained responses in patients who had exhausted approved treatment options. The combination of clinically meaningful antitumor activity and a differentiated safety profile – characterized by the absence of clinically significant myelosuppression, serious infections, neurologic or cardiopulmonary or severe ocular toxicity, or clinically meaningful hypertriglyceridemia – supports continued clinical development of nanoFenretinide. Dose escalation has been completed, a weekly dosing schedule is currently under evaluation, and correlative biomarker studies are ongoing.

Larisa J. Geskin, MD: Stratpharma - Research Funding; Trillium - Research Funding; Mallinckrodt - Research Funding; Kyowa Kirin International - Research Funding; Incyte - Research Funding; Innate - Research Funding; Soligenix - Research Funding; Johnson & Johnson - Research Funding; BMS - Research Funding; Merck - Research Funding; Scitech Development Inc - Consultancy (Includes expert testimony); Scitech Development Inc - Membership on a Board/Advisory Committee; Citius - Membership on a Board/Advisory Committee